Cancer Genome Atlas (TCGA) effort and other studies have shown that the mitogen-activated protein kinase (MAPK) pathway is ubiquitously activated in cutaneous melanoma as a result of somatic mutations in multiple genes, including point mutations in the v-Raf murine sarcoma viral oncogene homolog (BRAF) (35%-50% of melanomas) and neuroblastoma RAS viral oncogene homolog (NRAS) (10%-25%), and lossof-function mutations affecting neurofibromin 1 (NF1) (~15%). Efforts to target this pathway therapeutically culminated in the Food and Drug Administration (FDA) approval of the BRAF inhibitors vemurafenib and dabrafenib; the mitogen-activated protein kinase (MEK) inhibitor trametinib; and the combination regimens of dabrafenib + trametinib and vemurafenib + cobimetinib (Luke, Flaherty, Ribas, & Long, 2017) . All of these agents were approved specifically for melanoma patients with mutations that cause substitution of the V600 residue of the BRAF protein (Luke et al., 2017) . While the BRAF inhibitors, alone and in combination with MEK inhibitors, reduce tumor burden in almost all patients with a BRAF V600 mutation, most patients will eventually develop resistance (Gopal et al., 2014) . In addition to these targeted therapies, several immune therapies have also been approved for patients with metastatic melanoma in recent years, including the checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab, and the combination of ipilimumab and nivolumab (Luke et al., 2017) . Clinical responses and benefit with these immunotherapies can last for several years and may even be curative. However, the response rates with these immune therapies are lower than for the targeted therapies (i.e., 10%-15% for ipilimumab; 35%-45% for nivolumab and pembrolizumab; ~55% for ipilimumab + nivolumab) (Luke et al., 2017) . Thus, while there has been tremendous progress, there remains a need for additional effective therapeutic strategies for this disease.
There are a growing appreciation and data about the frequency and significance of metabolic reprogramming in cancer initiation, maintenance, and progression (Hanahan & Weinberg, 2011) . However, tumor metabolism is complex, and metabolic phenotypes may reflect both intrinsic properties of tumor cells and interactions between tumor cells and the tumor microenvironment (TME). Efforts to improve our understanding of this hallmark of cancer have produced encouraging results that deserve further investigation. Thus, this review will describe several of the central metabolic pathways that have been implicated in the pathogenesis of cutaneous melanoma. We will review the regulation of metabolic pathways by both oncogenic signaling in tumor cells and by the TME, and the therapeutic relevance and implications of the metabolic reprogramming of melanoma cells. Together, this information demonstrates that metabolic reprogramming contributes to the pathogenesis and heterogeneity of melanoma and that further study of cellular metabolism should be embraced in order to improve our understanding of, and treatments for, this highly aggressive disease.
| AN OVERVIEW OF CENTRAL CARBON METABOLIC PATHWAYS
Central carbon metabolism consists of glycolysis, the pentose phosphate pathway (PPP), and tricarboxylic acid (TCA) cycle (Pavlova & Thompson, 2016; Sudarsan, Dethlefsen, Blank, Siemann-Herzberg, & Schmid, 2014) (Figure 1 ). In normoxic, nonmalignant cells, a molecule of glucose undergoes the process of glycolysis in the cytosol to produce pyruvate, adenosine triphosphate (ATP), and reduced nicotinamide adenine dinucleotide (NADH) (Lehninger, Nelson, & Cox, 2013) .
Decarboxylation of pyruvate by mitochondrial pyruvate dehydrogenase (PDH) initiates the highly efficient process of mitochondrial oxidative phosphorylation (OXPHOS) by feeding acetyl coenzyme A (acetyl-CoA) into the TCA cycle (Lodish, 2000) . NADH and reduced flavin adenine dinucleotide (FADH2) molecules transfer electrons to the electron transport chain (ETC), which responds by transporting protons across the mitochondrial membrane (Lodish, 2000) . The resulting electrochemical gradient then drives ATP synthesis, with oxygen serving as the final electron acceptor, producing water as a byproduct (Lodish, 2000) ( Figure 1 ). As oxygen is necessary for the coupling of glycolysis and OXPHOS to occur, hypoxic cells rely more on glycolysis to meet their energy needs (Chatterjea & Shinde, 2012) .
In a process known as lactic acid fermentation, lactate dehydrogenase (LDH) transfers electrons from NADH to pyruvate, producing lactate and replenishing the supply of NAD + in the cytosol to allow further glycolysis to continue (Chatterjea & Shinde, 2012) . Melanoma cells take advantage of these available metabolic pathways, and others, by using them to meet their needs in a wide variety of contexts.
| UTILIZATION AND REGULATION OF METABOLIC PATHWAYS IN MELANOMA PROLIFERATION, INVASION, AND METASTASIS

| Glycolysis-an essential source of ATP and molecular precursors
Like many other cancer types, the majority of rapidly proliferating melanoma cells metabolize glucose into lactate regardless of oxygen levels, a process known as aerobic glycolysis, or the "Warburg effect," in honor of Otto Warburg, who first described the propensity of tumor cells to utilize glycolysis (Scott et al., 2011) . When glycolysis is utilized at high rates in proliferating tumor cells, it can supply the ATP necessary for survival while also supplying materials required for proliferation (Jose, Bellance, & Rossignol, 2011) . Scott et al. found that in normoxic conditions, only 25% of pyruvate enters the mitochondria of melanoma cells exhibiting the Warburg phenotype, where it is converted to acetyl-CoA by PDH (Scott et al., 2011) . Instead of fully circulating in the TCA cycle, the citrate is transported to the cytosol, where ATP citrate lyase (ACL) cleaves it into acetyl-CoA and oxaloacetate. Acetyl-CoA either enters the fatty acid synthesis pathway, which is critical for the proliferation of melanoma cells, or fuels acetylation of histones in epigenetic regulation reactions, while oxaloacetate is converted to malate, which produces pyruvate via malic enzyme and subsequently lactate via LDH (DeBerardinis & Chandel, 2016; Ratnikov, Scott, Osterman, Smith, & Ronai, 2017 (Porporato et al., 2014; Schwartz et al., 2010) .
Glycolysis also supports the PPP and serine/glycine synthetic pathway in melanoma cells. Glucose-6-phosphate dehydrogenase (G6PD) oxidizes glucose-6-phosphate (G6P), a glycolytic intermediate, in the rate-limiting step of the PPP (Lehninger et al., 2013) . After numerous additional reactions, the PPP produces a net gain of the reducing equivalent NADPH and 5-carbon sugars used in nucleotide synthesis. G6PD is highly expressed in melanomas, and inhibition of G6PD in A375 cells results in G1/S-phase cell cycle arrest due to ROS-mediated inhibition of signal transducer and activator of transcription 3 (STAT3) (Cai et al., 2015) . Phosphoglycerate dehydrogenase (PHGDH) catalyzes the initial step of the serine/glycine synthesis pathway, oxidizing the glycolytic intermediate 3-phosphoglycerate (3-PG). Serine plays a critical role in the biosynthesis of purines and pyrimidines, and it is the precursor of glycine. A bioinformatics analysis of 3,131 human cancer samples found recurring copy number gains in PHGDH at a frequency of 40% in melanomas, and melanomas with PHGDH copy number gains were particularly sensitive to PHGDH inhibition (Beroukhim et al., 2010; Locasale et al., 2011) .
The utilization of the Warburg phenotype by melanomas is driven in part by the activation of intrinsic signaling pathways, particularly the MAPK pathway (Table 1 ; Figure 1 ). Activation of the MAPK pathway increases the transcription of the hypoxia-inducible factor 1α (HIF1α) and v-MYC avian myelocytomatosis viral oncogene homolog (MYC) (Kumar et al., 2007; Parmenter et al., 2014) . Additionally, the MAPK pathway stabilizes HIF1α, allowing it to partner with HIF1β to become active and promote glycolysis via transcription of LDH, aldolase, and enolase 1 (ENO1) (Semenza et al., 1996) . Furthermore, HIF1α activates pyruvate dehydrogenase kinase (PDK), which inhibits PDH, F I G U R E 1 Signaling pathways promote melanoma progression by regulating critical metabolic reactions. Central carbon metabolism and one-carbon metabolism play critical roles in melanoma biology. Glycolysis produces ATP and intermediates that fuel the pentose phosphate pathway (PPP) and serine-glycine/one-carbon metabolism pathways, which produce NADPH vital for maintaining the redox balance of the cell and for anabolic reactions. The TCA cycle uses acetyl-CoA derived from pyruvate or β-oxidation of fatty acids to produce NADH, which powers the ATP-generating electron transport chain (ETC). The TCA cycle can also generate NADPH via isocitrate dehydrogenase 2 (IDH2). Like other tumor cells, the TCA cycle of melanoma cells can alternatively oxidize glutamine, which enters the TCA cycle as α-ketoglutarate (α-KG). In addition to its bioenergetic function, the TCA cycle produces critical biosynthetic precursors. Oxaloacetate (OAA) fuels reactions that generate NADPH via malic enzyme (ME) and also promotes nucleotide synthesis by supplying the cell with aspartate. Citrate provides the cell with acetyl-CoA necessary for fatty acid synthesis and acetylation reactions. Citrate also promotes NADPH production via isocitrate dehydrogenase 1 (IDH1). Signaling pathways play a critical role in determining which metabolic pathways are favored by melanoma cells. The MAPK and PI3K pathways promote glycolysis and the decoupling of glycolysis from the TCA cycle via HIF1α and MYC. However, through mechanisms currently unknown, a subset of melanomas highly expresses PGC1α, which promotes OXPHOS and makes the cells highly dependent on the oxidation of glutamine. GLUT1, glucose transporter 1; HK2, hexokinase 2; G6PD, glucose- (Kraehn et al., 2001 ).
The MYC transcription factor activates LDH, glucose transporter 1 (GLUT1), and hexokinase 2 (HK2), thereby promoting glucose uptake and glycolytic activity (Stine, Walton, Altman, Hsieh, & Dang, 2015; Zeller, Jegga, Aronow, O'Donnell, & Dang, 2003) . The MAPK pathway also promotes the Warburg phenotype through its inhibition of the microphthalmia-associated transcription factor (MITF), a critical regulator and promoter of OXPHOS in tumor cells (Haq et al., 2013) .
The phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) signaling pathway is activated multiple ways in melanoma, including by loss of function of the PTEN tumor suppressor, activating mutations in AKT and PIK3CA, and compensatory signaling through growth factor receptors (Davies et al., 2008; Guldberg et al., 1997; Kwong & Davies, 2013; Omholt, Krockel, Ringborg, & Hansson, 2006; Tsao, Zhang, Benoit, & Haluska, 1998 (Zundel et al., 2000) .
| Lactate/H + metabolism-a major contributor to melanoma metastasis
Produced at the end of glycolysis in order to maintain NAD + , lactate is subsequently secreted into the TME via monocarboxylate transporters (MCTs), with MCT4 as the most significant transporter (Dimmer, Friedrich, Lang, Deitmer, & Broer, 2000) . Pinheiro et al. demonstrated that GLUT1 and MCT4 overexpression significantly correlated with progression from primary tumor to lymph node metastasis in a cohort of patient-derived melanoma samples, indicating that the Warburg phenotype and lactate secretion cooperate to promote melanoma metastasis (Pinheiro et al., 2016) . In glycolytic tumor cells, HIF1α and MYC upregulate MCT4 to promote the secretion of lactate into the TME (Payen, Porporato, Baselet, & Sonveaux, 2016; Ullah, Davies, & Halestrap, 2006) . Lactate drastically alters the TME, facilitating angiogenesis, promoting metastasis, and suppressing the immune system (Romero-Garcia, Moreno-Altamirano, Prado-Garcia, (Payen et al., 2016; Sonveaux et al., 2012; Vegran, Boidot, Michiels, Sonveaux, & Feron, 2011) (Figure 2 ).
Intracellular protons produced via dissociation of lactic acid are secreted into the melanoma TME via sodium-proton exchanger 1 (NHE1), lowering the pH of extracellular space (Payen et al., 2016; Stuwe et al., 2007; Vahle et al., 2014) . Additional membrane protein complexes, including carbonic anhydrase IX (CAIX), sodium bicarbonate transporter 1, and anion exchanger 2 (AE2), also contribute to extracellular acidosis (Alper, Chernova, & Stewart, 2002; Benej, Pastorekova, & Pastorek, 2014; Donowitz, Ming Tse, & Fuster, 2013; Payen et al., 2016; Pinheiro et al., 2016) (Figure 2 ).
Acidification of the TME facilitates melanoma metastasis in several ways. First, a low extracellular pH promotes the formation of collagenintegrin interactions in the lamellipodia of melanoma cells, allowing focal adhesion complexes to form and increasing migration of melanoma cells (Payen et al., 2016; Stock et al., 2005) . In addition, extracellular acidosis disrupts cellular junctions through the induction of matrix metalloproteases (MMPs) 2 and 9 and cathepsins B and L, which are secreted into the TME as inactive zymogens and require a low pH to be activated (Rofstad, Mathiesen, Kindem, & Galappathi, 2006) (Figure 2 (Rofstad et al., 2006) . As further evidence, inhibition of NHE1 in vitro prevented the invasive behaviors of melanoma cells to a significantly greater extent than vehicle controls (Stuwe et al., 2007; Vahle et al., 2014) . Additionally, inhibitors of AE2 and CAIX block invasiveness of a variety of other tumor cell types (Klein, Seeger, Schuricht, Alper, & Schwab, 2000; Lagana et al., 2000; Payen et al., 2016; Svastova et al., 2012) . The direct effects of lactate metabolism on the immune system will be covered more extensively later in this review.
| Oxidative phosphorylation (OXPHOS)-a driver of growth and progression in subsets of human melanomas
While many melanomas are characterized by the Warburg phenotype, OXPHOS also plays a critical role in melanoma. OXPHOS is significantly more efficient at generating ATP than glycolysis. While only 7%
of pyruvate accesses the TCA cycle in hypoxic cells, OXPHOS still contributes a significant portion of ATP to these cells as large quantities of ATP are produced from a few molecules of pyruvate (Scott et al., 2011) .
Melanoma cell metabolism promotes disease progression by shaping the tumor microenvironment. The secretion of lactate into the tumor microenvironment (TME) by monocarboxylate transporter 4 (MCT4) results in immunosuppression and angiogenesis, facilitating tumor progression. Lactate inhibits CD8 + T-cell proliferation and function, prevents the maturation of dendritic cells, and converts M1 macrophages to M2 macrophages. It also facilitates angiogenesis by increasing IL-8 and VEGF signaling in endothelial cells. Tryptophan metabolism further promotes immunosuppression via depletion of tryptophan and secretion of kynurenine into the TME. Acidification of the TME via proton transport activates cathepsins and matrix metalloproteases (MMPs), which promote migration and metastasis through degradation of the extracellular matrix. IFN-γ, interferon-gamma; IFN-γ R, interferon-gamma receptor; GLUT1, glucose transporter 1; NHE-1, sodium-hydrogen antiporter 1; SLC5A1, solute carrier family 5 member 1; NBC, sodium-coupled bicarbonate transporter; CAIX, carbonic anhydrase 9; IDO, indoleamine 2,3-dioxygenase; OAA, oxaloacetate; α-KG, α-ketoglutarate. Visual Art: © 2017 The University of Texas MD Anderson Cancer Center
Furthermore, a subset of melanomas rely extensively on OXPHOS to meet their bioenergetic needs. Our laboratory and others have identified that between 35% and 50% of BRAF-mutant and wild-type cell lines and patient samples can be characterized as "High-OXPHOS" (Gopal et al., 2014; Haq et al., 2013; Zhang et al., 2016) . This phenotype is predominantly driven by peroxisome proliferator-activated receptor γ 1-α (PPARGC1A, named hereafter PGC1α), a transcriptional cofactor that regulates multiple mitochondrial genes. Examination of PGC1α gene expression in the Broad Cancer Cell Line Encyclopedia (CCLE) database revealed that melanomas have the highest expression of PGC1α among >900 cell lines representing 23 cancer types (Gopal et al., 2014) . Melanomas highly expressing PGC1α also express numerous nuclear respiratory factors, mitochondrial transcriptional factors, mitochondrial DNA replication factors, mitochondrial fission mediators, and mitochondrial fusion mediators (Zhang et al., 2016) . Elevated
PGC1α significantly correlates with decreased overall survival in patients with stage III melanoma (Vazquez et al., 2013) . As detailed later in this review, basal and compensatory upregulation of PGC1α expression also correlates with de novo and acquired resistance to MAPK pathway inhibitors (Gopal et al., 2014; Zhang et al., 2016) . Also, PGC1α-high melanoma cells tolerate oxidative stress to a significantly greater extent than PGC1α-low cells (Vazquez et al., 2013) . PGC1α expression is regulated by MITF in melanoma cells (Haq et al., 2013) . HIF1α prevents the transcription of MITF in glycolytic melanomas through deleted in esophageal cancer 1 (DEC1) (Abildgaard & Guldberg, 2015; Feige et al., 2011) . In High-OXPHOS melanomas, however, this regulation fails to occur ( Figure 1 ).
Instead, mTOR promotes the nuclear translocation of MITF, which drives the transcription of PGC1α and, subsequently, OXPHOS genes (Table 1; Figure 3 ) (Gopal et al., 2014; McQuade & Vashisht Gopal, 2015) . mTOR is the core component of two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Shimobayashi & Hall, 2014) . The PI3K/AKT pathway activates both complexes by suppressing inhibitory inputs from tuberous sclerosis complexes 1/2 (TSC1/2) (Shimobayashi & Hall, 2014) . mTORC1 also becomes active in the presence of amino acids. Once active, mTORC1 phosphorylates ribosomal protein S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), promoting protein synthesis, including the translation of MYC and HIF1α (Shimobayashi & Hall, 2014) . Active mTORC2 primarily functions to phosphorylate AKT at serine 473, resulting in further activation of AKT (Shimobayashi & Hall, 2014) . These interactions have F I G U R E 3 mTOR regulates the subcellular localization of MITF. In our prior studies, High-OXPHOS MEL624 cells underwent 24-hr treatments with DMSO (Mock), the MEKi selumetinib (SEL), the mTORC1/2 inhibitor AZD8055, and selumetinib + AZD8055 (SEL + AZD8055).
To identify the subcellular localization of MITF following each treatment, cells were fixed and probed with MITF antibody and stained with a FITC-labeled secondary antibody. Nuclei were stained with DAPI. Images were evaluated via immunofluorescent microscopy. AZD8055 caused a significant increase in cytoplasmic MITF staining and a significant decrease in nuclear MITF staining, compared with mock treatments. In contrast, nuclear staining of MITF increased in MEL624 cells treated with selumetinib, relative to mock treatments. Gene expression profiling experiments demonstrated that 24-hr selumetinib treatments markedly increased MITF and PGC1α transcript levels in MEL624 cells, while AZD8055 inhibited basal and selumetinib-induced PGC1α expression. Image reused with permission (Gopal et al., 2014 ). An illustration of the mTOR/MITF/PGC1α signaling axis can also be viewed in one of our prior reviews (McQuade & Vashisht Gopal, 2015) been shown to promote protein synthesis, lipid synthesis, nucleotide synthesis, and glycolysis (Shimobayashi & Hall, 2014) . mTOR is also known to increase mitochondrial activity and OXPHOS via activation of YYI-PGC1α transcriptional complex (Cunningham et al., 2007) . How mTORC1/2 signaling selects between promoting glycolysis or OXPHOS remains unclear.
AMP-activated protein kinase (AMPK) expression also positively correlates with PGC1α expression (Shackelford & Shaw, 2009) . In low cellular energy states, designated by a high ratio of AMP to ATP, liver kinase B1 (LKB1) activates AMPK, which inhibits anabolic reactions by suppressing mTORC1 and promotes mitochondrial gene expression, likely through PGC1α (Canto et al., 2009; Shackelford & Shaw, 2009 ).
While the mechanism by which AMPK acts through PGC1α remains unclear, one possibility is that AMPK directly drives PGC1α expression (Canto et al., 2009 ). Alternatively, AMPK could promote PGC1α activation by either direct phosphorylation or indirectly through sirtuin-1 (SIRT1)-mediated deacetylation (Canto et al., 2009; Jager, Handschin, St-Pierre, & Spiegelman, 2007) . In glycolytic tumors, phosphorylated ERK (pERK) suppresses the activation of LKB1, inhibiting the typical response to energy deficiency (Zheng et al., 2009 ). These cells are less responsive to high AMP/ATP ratios and less dependent on OXPHOS to meet their bioenergetic needs. It is likely that suppression of LKB1 also inhibits PGC1α expression, although this has not been tested.
| TCA cycle metabolism-a supplier of cellular building blocks
While mitochondria serve as the primary bioenergetic source for a subset of melanomas, functional mitochondria are critical for all melanoma cells by providing intermediates utilized by biosynthetic and redox reactions (Wallace, 2012) . In addition to producing the fatty acid precursor citrate via condensation with acetyl-CoA, oxaloacetate produced from the TCA cycle is converted to aspartate via transamination reactions involving glutamate. This aspartate cooperates with malate, another TCA intermediate, to power the malate-aspartate shuttle, which moves NADH from glycolysis to the mitochondria (Lehninger et al., 2013) . Furthermore, aspartate transported into the cytosol by the shuttle contributes to the synthesis of nucleic acids utilizes aspartate to produce arginosuccinate in the urea cycle. As a result, cytoplasmic levels of aspartate increased, activating carbamoyl phosphate synthetase II (CAD), the rate-limiting enzyme in pyrimidine synthesis, thereby facilitating the synthesis of nucleotides and promoting melanoma cell proliferation (Rabinovich et al., 2015) .
To continue utilizing citrate and oxaloacetate as biosynthetic precursors, melanoma cells must replenish TCA intermediates in a process called anaplerosis (Owen, Kalhan, & Hanson, 2002 2015) . Instead, these cells utilize glutamine as the primary source of carbon entering the TCA cycle (Scott et al., 2011) . Upon transport into the cell via the glutamine receptor SLC1A5, glutamine is converted to glutamate via cytosolic glutaminase (Ratnikov et al., 2017) .
Glutamate enters the TCA cycle as α-ketoglutarate via reactions catalyzed by either glutamate dehydrogenase 1 (GDH) or mitochondrial alanine and aspartate aminotransferase (GOT2 and GPT2, respectively) (Ratnikov et al., 2015) . Reactions catalyzed by GDH generate free ammonia, which can promote autophagy, while the aminotransferases transfer nitrogen to α-keto acids to form α-ketoglutarate and amino acids. Ratkinov et al. labeled Lu1205 melanoma cells with 13 C-glutamine to demonstrate that GDH and aminotransferases interchangeably catalyze this anaplerotic reaction and can maintain anaplerosis upon suppression of the alternative route (Ratnikov et al., 2015) . A great deal of attention has been placed on IDH1 and IDH2 in recent years as heterozygous mutations have been identified at R132 in the cytosolic IDH1 and at R172 in mitochondrial IDH2 in glioblastoma and acute myeloid leukemia (Abbas et al., 2010; Filipp et al., 2012a; Mardis et al., 2009; Parsons et al., 2008) . These mutated enzymes produce 2-hydroxyglutarate (2-HG) from alpha-ketoglutarate. 2-HG acts as an oncometabolite by inducing a variety of epigenetic changes in the tumor cells (Filipp et al., 2012a; Rakheja, Medeiros, Bevan, & Chen, 2013) . Mutations in IDH1/2 are rare in melanoma and typically affect IDH1 (Filipp et al., 2012a; Lopez et al., 2010 
| Protein/amino acid metabolism-arginine, proline, and proteasomal degradation in human melanomas
In addition to glutamine and aspartate, a considerable amount of amino acid research in melanoma has focused on arginine and proline. Interestingly, melanomas cannot synthesize their own arginine, as they lack expression of arginine synthetase (Dillon et al., 2004) .
Thus, they are solely dependent on external sources of arginine in the TME for protein synthesis (Delage et al., 2010) . protein in the cells resulted from increased ubiquitin-mediated proteasomal degradation (Anwar, Norris, & Fujita, 2011) . Their attempts at disrupting this uncontrolled degradation of p53 protein triggered G1 cell cycle arrest in the 8B20 cells (Anwar et al., 2011) . Similarly, nutlins are a class of compounds that disrupt the interactions between MDM2 and p53. By preventing the unregulated degradation of p53, nutlin-3 restores p53 levels in human melanoma cell lines, regardless of p53 mutational status (Ji et al., 2012; Worrall et al., 2017) . However, nutlin-3 selectively decreases the viability of cells with wild-type p53 (Ji et al., 2012; Worrall et al., 2017) . Interestingly, nutlin-3 treatment increases cellular levels of MDM2, resulting in ubiquitination and degradation of insulin-like growth factor type 1 receptor (IGF-1R) (Worrall et al., 2017) . The disruption of the IGF-1R signaling axis causes an initial increase in melanoma cell proliferation but ultimately suppresses proliferation and inhibits migration (Worrall et al., 2017) . These examples demonstrate the tendency of melanoma cells to hijack common cellular machinery to promote their own survival and how doing so makes them vulnerable to novel classes of therapeutics.
| Lipid metabolism-synthesis and degradation of fatty acids promotes melanoma progression
Fatty acid synthase (FASN) catalyzes the rate-limiting step of the endogenous synthesis of fatty acids (Menendez & Lupu, 2007) . FASN is positively regulated in normal tissue by insulin and hormones such as estrogen and progesterone and negatively regulated by leptin, which in turn is stimulated by free fatty acids (FFAs) (Kersten, 2001; Kim et al., 1998; Menendez & Lupu, 2007) . Insulin, estrogen, and progesterone activate the transcription factor sterol regulatory element-binding protein 1c (SREBPC1c), which is responsible for driving FASN transcription (Kersten, 2001; Kim et al., 1998; Menendez & Lupu, 2007) . In many tumor types, including melanoma, SREBPC1c is constitutively driven by the MAPK and PI3K/AKT pathways, which causes significant upregulation of FASN (Kersten, 2001; Kim et al., 1998; Menendez & Lupu, 2007) (Table 1 ; Figure 1 ). These signaling pathways promote the maturation of SREBP1c from its precursors and its nuclear localization from the Golgi apparatus following its maturation (Menendez & Lupu, 2007) . The increased FASN is believed to provide a survival benefit to tumor cells by promoting a "lipogenic better than parental cells (Thomas et al., 1996) . Furthermore, ganglioside GD3 − SK-MEL-28-N1 melanoma cells became significantly more proliferative and invasive following transfection with GD3 via stimulation of p130Cas and paxillin signaling (Hamamura et al., 2005) . siRNAmediated knockdown of p130Cas and paxillin subsequently inhibited ganglioside GD3 signaling in these cells, although the effects remain to be validated in vivo (Hamamura et al., 2005) .
In addition to the synthesis of fatty acids, fatty acid oxidation (FAO) appears to play an important role in promoting melanoma progression. For example, carnitine palmitoyltransferase 2 (CPT2), the enzyme critical for translocation of long-chain fatty acids (LCFAs) in preparation for β-oxidation, is one of the most significantly upregulated genes in melanomas, relative to benign nevi (Sumantran et al., 2015) . Furthermore, Rodrigues et al. derived metastatic 4C11 + cells from melan-a melanocytes after sequential detachment-re-adhesion cycles, and FAO contributed significantly to the energy reserves of these 4C11 + cells, relative to non-metastatic controls (Rodrigues et al., 2016) . How FAO promotes melanoma progression remains unclear.
Studies in other tumor types have demonstrated that fatty acids can
provide an ATP boost for tumor cells when necessary under nutrientdepleted conditions (Carracedo, Cantley, & Pandolfi, 2013; Carracedo et al., 2012; Zaugg et al., 2011) . Indeed, the process of metastasis is a highly demanding process. Highly efficient β-oxidation could provide a survival advantage for cells away from the primary tumor site.
Furthermore, fatty acids can serve as a valuable source of acetyl-CoA that contributes to citrate formation after entering the TCA cycle (Carracedo et al., 2013) . As detailed earlier, this citrate can enter metabolic reactions that produce NADPH via IDH1, thereby contributing to redox balance in the tumor cells.
Numerous lipid-derived second messengers such as phospholipase D3 (PLD3), inositol triphosphate protein kinase B (ITPKB), and inositol triphosphate receptor 3 (ITPR3) are significantly upregulated in melanomas, relative to benign nevi (Sumantran et al., 2015) . Furthermore, ITPKB is significantly upregulated in MALME_3M and UACC_257 melanoma cell lines of the National Cancer Institute (NCI) Cell Miner database (Sumantran et al., 2015) . Additionally, fatty acid binding proteins, which are regulators of fatty acid uptake and lipid trafficking, appear to play important roles in melanoma progression. Fatty acid binding protein 3 (FABP3) expression is threefold higher in melanomas than in benign nevi (Sumantran et al., 2015) . Furthermore, Slipicevic et al.
demonstrated that fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells in vitro (Slipicevic et al., 2008) . siRNA-mediated suppression of FABP7 inhibited invasion and proliferation of melanoma cells without affecting apoptosis (Slipicevic et al., 2008) . However, the relevance of FABP7 in in vivo models of metastasis remains to be validated.
Finally, Nath and Chan identified a crucial role for fatty acid metabolism in melanoma progression while deriving a gene signature to detect activation of epithelial-mesenchymal transition (EMT)
programming across multiple cancers (Nath & Chan, 2016) . TCGA melanoma patients enriched in the authors' 5-gene signature, which included the fatty acid uptake genes caveolin-1 (CAV1) and cluster of differentiation 36 (CD36) and the fatty acid oxidation gene carnitine palmitoyltransferase 1C (CPT1C), have significantly worse overall survival than those whose melanomas are not enriched for the signature (Nath & Chan, 2016) . Additionally, CD36 amplifications significantly correlate with invasiveness in 501mel melanoma cells (Nath & Chan, 2016; Pascual et al., 2017) . In contrast, melanoma cells lacking CD36 fail to metastasize in NOD scid gamma (NSG) mice following tail vein inoculation (Pascual et al., 2017) . These studies further implicate lipid metabolism in the progression of human melanoma.
| One-carbon metabolism-a critical deterrent of oxidative stress
Melanoma cells are subjected to oxidative stress, with ROS formed secondary to oncogenic mutations, aberrant signaling pathways, unregulated proliferation, and hypoxia (DeBerardinis & Chandel, 2016) .
While minimal levels of ROS are actually beneficial to these cells by stimulating proliferation and inducing mutations, excessive ROS can induce damage and eventually apoptosis (DeBerardinis & Chandel, 2016) . As oxidative stress increases during tumorigenesis progression and metastasis, melanoma cells must adjust and strengthen their antioxidant defenses to survive (Gorrini, Harris, & Mak, 2013) . In addition to activating nuclear factor (erythroid-derived 2)-related factor-2 (NRF2) to drive the transcription of antioxidant proteins, tumor cells increase their reliance on glutathione peroxidase to manage oxidative stress (Jaramillo & Zhang, 2013) . This protein utilizes reduced glutathione (GSH) to convert peroxides to water. Glutathione reductase utilizes NADPH to restore GSH to its oxidized state (GSSG), making NADPH a critical component of redox balance in melanoma cells.
Early in tumorigenesis, the PPP supplies the majority of the NADPH used by this enzyme. Together with NRF2-regulated genes, the PPP is sufficient to manage the oxidative stress secondary to intense proliferation. However, the role of one-carbon metabolism, mediated by the folate cofactor, becomes increasingly important as tumorigenesis progresses, glucose becomes scarce, and hypoxia becomes a more significant source of ROS (DeBerardinis & Chandel, 2016) . In this pathway, serine is converted to glycine via serine hydroxymethyltransferase (SHMT1) in a reaction that also converts tetrahydrofolate 
| IMPACT OF THE TUMOR MICROENVIRONMENT ON TUMOR METABOLISM
| Metabolic adaptation to nutrient-depleted conditions
While it is most convenient to classify melanomas as either glycolytic or oxidative, an increasing body of evidence suggests that metabolic phenotypes of tumors are more accurately viewed as dynamic in nature (Jose et al., 2011) . While key oncogenic pathways implicated in melanomas (RAS-RAF-MAPK and PI3K/AKT) typically promote glycolysis, this metabolic pathway requires an extensive supply of glucose to fuel reactions. Tumor cells are not equally supplied with oxygen and nutrients due to inadequate vascularization, and frequently, they must adapt to hypoxia and to glucose deprivation (Jose et al., 2011) .
In the presence of adequate glucose, hypoxic melanoma cells almost completely decouple glycolysis from the TCA cycle (Scott et al., 2011) .
Glutamine fuels the TCA cycle and provides citrate for fatty acid synthesis, while glutamine and glucose oxidation contributes over 90%
of ATP to the cell (Scott et al., 2011) . Alternative pathways such as glutamine and fatty acid oxidation are essential in glucose-depleted conditions. For example, adipocytes in the TME can communicate with melanoma cells via exosomes carrying proteins involved in FAO (Lazar et al., 2016) . Upon uptake by melanoma cells, via an uncharacterized mechanism, these exosomes force a metabolic reprogramming in melanoma cells characterized by high levels of FAO and aggressiveness (Lazar et al., 2016) . Studies in other cancer types have provided numerous insights into the role of the TME in shaping tumor cell metabolism. For example, the MDA-MB-231Br3 cell line, derived from MDA-MB-231 parental cells after three rounds of in vivo selection from brain metastases following injections into the internal carotid artery, adapted to the glucose-deprived conditions of the brain TME by becoming dependent on gluconeogenesis and oxidation of glutamine and branched-chain amino acids instead of glycolysis . (Chaube et al., 2015) .
Analysis of the TCGA melanoma dataset identified three broad categories of melanomas: "Immune," "Keratin," and "MITF-low" subtypes (Cancer Genome Atlas Network, 2015). The MITF-low melanomas express numerous genes involved in invasion and migration (Cancer Genome Atlas Network, 2015) . In vitro analyses have demonstrated that temporary suppression of MITF triggers a slow-cycling, invasive phenotype, while long-term suppression of MITF results in senescence (Cheli et al., 2011; Giuliano et al., 2010) . However, MITFlow cells do not experience senescence in vivo (Goodall et al., 2008; Riesenberg et al., 2015) . In studying this paradox, Falletta et al. de- termined that distressed melanomas increase cellular levels of activating transcription factor 4 (ATF4), which subsequently suppresses MITF and prevents senescence (Falletta et al., 2017) . Further experiments determined that glutamine deprivation activated the aforementioned response (Falletta et al., 2017) . Specifically, glutamine deprivation resulted in a transient increase in MITF gene expression due to calmodulin-dependent kinase II (CAMKII)-mediated stimulation of cyclic AMP response element-binding protein (CREB) (Falletta et al., 2017) . The MAPK pathway subsequently phosphorylated MITF, which promoted ATF4 transcription (Falletta et al., 2017) . In parallel, eIF2B suppression triggered a global reprogramming that involved further suppression of MITF and increased expression of ATF4 and was necessary for MITF-low cells to invade (Falletta et al., 2017 
2017).
Together, these findings demonstrate how nutrient supply in the TME induces significant changes in signaling pathways that drive metastasis.
In recent years, the role of autophagy and macropinocytosis in promoting survival of melanoma cells in hostile microenvironments has gained considerable interest. Autophagy is a highly regulated process that involves the degradation of macromolecules and organelles into useful constituent components. In this manner, large proteins can be degraded to provide nitrogen and carbon for bioenergetic maintenance. MEK/ERK signaling in melanoma upregulates phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), which promotes an increase in autophagy through cAMP-responsive element-binding protein (CREB) (Liu et al., 2014; Ndoye & Weeraratna, 2016) . NOXAdriven autophagy delays the apoptosis of human melanoma cells in nutrient-depleted conditions (Liu et al., 2014) . Furthermore, autophagy provides a survival advantage to melanoma cells cultured in harsh, acidic conditions (Marino et al., 2012; Ndoye & Weeraratna, 2016) . In 
| Lactate shuttling-an untapped avenue in melanoma metabolism
Directly in contrast with the Warburg effect, the reverse Warburg effect was originally proposed by Pavlides et al. (2009) Mitochondrial activity in the CAFs is inhibited, forcing the cells to depend exclusively on glycolysis. These cells secrete lactate into the TME via MCT4, which tumor cells take up via MCT1 to fuel oxidative metabolism Pavlides et al., 2009 Pavlides et al., , 2010 . (Ho et al., 2012) . Together with the evidence of dependence on OXPHOS in melanoma metastasis, these findings suggest that metabolic symbiosis could play a role in melanoma progression, and a potential therapeutic opportunity. For example, inhibition of MCT1 in a mouse model of lung carcinoma resulted in oxygenated cells switching to glycolysis for ATP production. As a result, hypoxic tumor cells died secondary to glucose starvation (Sonveaux et al., 2008) .
| IMMUNE EFFECTS OF METABOLIC REPROGRAMMING
As immune cells compose a critical component of the TME, there is an increasing interest in studying the metabolic interactions that occur between melanoma cells and immune cells. To fully understand the complexity of these dynamic interactions, it is necessary to review the typical metabolic statuses of the key immune cells present in the TME. (Pearce & Pearce, 2013) . T cells, the most researched component of the adaptive immune system, utilize a spectrum of metabolic phenotypes depending on their activation state and the subclass of T cells to which they belong. Activated CD4 + and CD8 + effector T cells adopt a glycolytic phenotype, upregulating glucose transporters and glycolytic enzymes in the process .
Unlike cells of the innate immune system, T cells produce memory cells, which catabolize fatty acids and utilize OXPHOS to produce ATP (Romero-Garcia et al., 2016) . Regulatory CD4 + T cells (Tregs) are highly oxidative cells, while regulatory T helper-17 (Th17) cells depend on glycolysis (Pearce & Pearce, 2013) . While much work remains to fully understand the metabolic dependencies of B lymphocytes, these cells appear to utilize both OXPHOS and glycolysis (Romero-Garcia et al., 2016) .
Tumor metabolism can suppress the function of nearby immune cells ( Figure 2 ). As CD8 + T cells are glycolytic, they must compete with highly glycolytic tumor cells for access to glucose (Chang et al., 2015) . Without glucose, CD8 + T-cell activity is inhibited.
Furthermore, high concentrations of lactate in the TME prevent adequate secretion of lactate out of T cells, again inhibiting their function (Fischer et al., 2007; Romero-Garcia et al., 2016) . By inducing P38 MAPK and c-Jun N-terminal kinase (JNK)/c-JUN signaling pathways, lactate-based immunosuppression has been demonstrated in numerous cancers, including melanoma (Mendler et al., 2012; Romero-Garcia et al., 2016) . Melanoma spheroids inhibit cytokine secretion from T cells by secreting lactate into the TME (FederMengus et al., 2007; Romero-Garcia et al., 2016) . However, T cells can recover from this inhibition upon lactate clearance (Fischer et al., 2007) . Lactate can also suppress cells of the innate immune system. It converts M1 macrophages to M2 macrophages, promoting tumor progression (Romero-Garcia et al., 2016) . In addition, it prevents the maturation of dendritic cells, resulting in an increase in the immunosuppressive IL-10 cytokine in the TME (Romero-Garcia et al., 2016) .
Tumor cell metabolism can also profoundly impact the immune system via tryptophan metabolism. Once activated, effector T helper 1 (Th1) cells secrete interferon-γ (IFN-γ), which stimulates indoleamine 2,3-dioxygenase (IDO) in tumor cells. In turn, IDO metabolizes tryptophan, producing kynurenine in the process. IDO promotes melanoma tumorigenesis and diminishes survival through two mechanisms (Brody et al., 2009; Sucher et al., 2010) . First, IDO starves effector T cells of tryptophan, resulting in general control non-derepressible 2 (GCN2)-mediated suppression of proliferation and promotion of apoptosis (Lee et al., 2002; Munn & Mellor, 2016; Munn et al., 2005; Sucher et al., 2010) . While a minimum level of tryptophan for T-cell maintenance has not been demonstrated, low serum tryptophan levels correlate with a poor prognosis in patients with melanoma (Sucher et al., 2010; Weinlich, Murr, Richardsen, Winkler, & Fuchs, 2007) . In addition, kynurenine binds to the aryl hydrocarbon receptor (AhR), inducing Treg differentiation and polarizing dendritic cells and macrophages to immunosuppressive phenotypes (Mezrich et al., 2010; Munn & Mellor, 2016) . Moreno et al. demonstrated that targeting IDO with the competitive inhibitor 1-methyl-tryptophan (1-MT) retards the proliferation of melanoma cells in vitro (Moreno et al., 2013) . Furthermore, 1-MT treatment delays the outgrowth of Lewis lung cancer cells in syngeneic mice (Friberg et al., 2002) . Although monotherapy with 1-MT has little effect on the growth of subcutaneous B16-F10 tumors, 1-MT sensitizes the tumors to chemotherapy and whole-body radiation (Hou et al., 2007) . While promising, additional exploration is required to further define how IDO mediates immunosuppression in melanoma and whether or not 1-MT can be combined with currently approved therapies.
| THERAPEUTIC IMPLICATIONS OF MELANOMA METABOLISM
The development of effective immune and targeted therapies has revolutionized the management of patients with metastatic melanoma.
However, these treatments have metabolic implications that must be understood in order to identify potential mechanisms of resistance and novel treatment combinations.
| Immunotherapy
Metabolic signaling inhibiting PI3K (Parry et al., 2005) . As this pathway promotes glycolysis, CTLA-4 and PD-1 signaling promote OXPHOS at the expense of glycolysis, and PD-1 signaling augments fatty acid oxidation (Patsoukis et al., 2015) . As activated effector T cells utilize glycolysis, these metabolic alterations provide a metabolic explanation for CTLA-4-and PD-1-mediated immunosuppression. Checkpoint inhibitors remove the suppression of the PI3K/AKT in effector T cells, allowing them to become active once again and adopt a glycolytic phenotype.
Once this occurs, tumor cell death caused by the checkpoint inhibitors results in the release of glucose into the TME, promoting further activation of effector CD8 + T cells (Chang et al., 2015) . It remains to be seen whether directly inhibiting glycolysis in tumor cells will improve the efficacy of checkpoint inhibitors.
In addition to central carbon metabolism, tryptophan metabolism also appears to play a critical role in mediating response to Furthermore, IDO inhibitors synergized with anti-CTLA-4 treatment, promoting CD8 + T-cell recruitment and inhibiting tumor growth to a significantly greater extent than anti-CTLA-4 treatment alone (Holmgaard, Zamarin, Munn, Wolchok, & Allison, 2013) . When given to 19 treatment-naive metastatic melanoma patients participating in a phase I clinical trial (NCT02178722), the combination of pembrolizumab and the IDO inhibitor epacadostat achieved complete responses in four patients, partial responses in seven patients, and stable disease in three patients (Gangadhar et al., 2016) . Furthermore, the combination demonstrated an acceptable safety profile (Gangadhar et al., 2016) . Treatment-naive metastatic melanoma patients are currently being enrolled in phase II and III clinical trials (NCT02752074) designed to evaluate this treatment strategy.
| Targeted therapy
While the BRAF inhibitors dabrafenib and vemurafenib and the MEK inhibitors trametinib and cobimetinib are highly effective in metastatic melanoma patients with activating BRAF mutations, the depth and duration of clinical responses to these agents are variable, and the majority of patients will eventually develop resistance to them (Gopal et al., 2014) . to longer (i.e., ≥72 hr) treatments with MAPK inhibitors (Haq et al., 2013) . Induction of OXPHOS has been identified in 30%-50% of BRAF-mutant melanomas with both de novo and acquired resistance to MAPK pathway inhibitors (Gopal et al., 2014) . Enforced expression of PGC1α induces resistance in cells previously sensitive to MAPK inhibitors (Haq et al., 2013) , while genetic knockdown of PGC1α results in synergistic growth inhibition and apoptosis induction with MAPK pathway therapies in PGC1α-mediated High-OXPHOS cells (Gopal et al., 2014) . In addition, studies by Herlyn and colleagues previously identified a population of slow-cycling, treatment-resistant cells characterized by expression of the histone 3 K4 demethylase JARID1B.
They further showed that these slow-cycling cells are characterized by High-OXPHOS. Interestingly, transcription factor A, mitochondrial (TFAM), not PGC1α, facilitates the High-OXPHOS phenotype in these cells, indicating that some High-OXPHOS melanoma cells adopt this metabolic phenotype independent of the MITF/PGC1α signaling axis (Roesch et al., 2010 (Roesch et al., , 2013 Zhang et al., 2016) . Combination treatments with vemurafenib and mitochondrial inhibitors overcame the multidrug resistance of JARID1B high cells in vitro (Roesch et al., 2013) .
This strategy of targeting both the MAPK pathway and OXPHOS has been highly effective in other studies as well. For example, our laboratory determined that the High-OXPHOS phenotype predicts sensitivity to combination treatment with MAPK pathway inhibitors and mTORC1/2 inhibitors (Gopal et al., 2014) . Mechanistically, mTORC1/2 inhibitors prevented the nuclear translocation of MITF, thereby inhibiting PGC1α transcription (Figure 3 ; Gopal et al., 2014) . Similarly, directly targeting mitochondrial biogenesis with the mitochondriatargeted, small-molecule HSP90 inhibitor gamitrinib has also been shown to overcome MAPK pathway resistance in melanomas with the High-OXPHOS phenotype (Zhang et al., 2016) .
Numerous studies have also examined the effects of the biguanide metformin as a combinatorial strategy in melanoma. Commonly used for the treatment of diabetes mellitus type 2, metformin became the subject of extensive oncological research after an initial report indicated that diabetic patients treated with metformin had lower rates of cancer (Pulito et al., 2013) . As an inhibitor of complex I of the mitochondrial electron transport chain, metformin deprives cells of ATP, stimulating AMPK and resulting in mTOR inhibition, p53 activation, and apoptosis (Cerezo, Tomic, Ballotti, & Rocchi, 2015) . Furthermore, metformin independently inhibits mTOR likely through a RAS-related
GTPase and suppresses NFκB-STAT3 signaling (Cerezo et al., 2015) .
Experiments testing metformin as a single-agent therapy have produced mixed results (Cerezo et al., 2015) . While several studies demonstrated the antimelanoma effect of metformin therapy in vitro, Martin et al. found that metformin treatments promoted the growth of BRAF V600E -mutated melanomas in vivo by inducing angiogenesis (Janjetovic et al., 2011; Martin, Hayward, Viros, & Marais, 2012; Niehr et al., 2011; Tomic et al., 2011) . Despite this effect, metformin treatment also sensitized melanoma cells to treatment with angiogenesis inhibitors (Martin et al., 2012) . Other combination studies have been very promising, with Niehr et al. demonstrating synergy between vemurafenib and metformin in BRAF V600E -mutated melanomas (Niehr et al., 2011) . Currently, two phase I/II trials are enrolling patients to test combinations of vemurafenib and metformin (NCT01638676) and dabrafenib, trametinib, and metformin (NCT02143050) in metastatic melanoma patients.
Recent work also supports that BRAF inhibitor-resistant, High-OXPHOS melanomas prefer glutamine metabolism over glucose metabolism (Baenke et al., 2016) . This finding suggests a new therapeutic opportunity, and experiments demonstrated that the glutaminase inhibitor BPTES enhanced the antitumor effects of MAPK pathway inhibitors in the treatment of these High-OXPHOS melanomas (Baenke et al., 2016) . While promising, additional work remains to understand optimal dosing of treatment combinations with targeted therapies and metabolic inhibitors.
| CONCLUSIONS
The understanding of metabolic reprogramming in melanoma has expanded significantly in recent years. Much of this work has focused on the regulation and roles of glycolysis and OXPHOS, which appear to be critical to many processes involved in melanoma maintenance, progression, and resistance. However, numerous additional metabolic pathways have been identified that promote melanoma survival, allowing adaptation to a wide range of environments. These pathways should be evaluated further to improve our understanding of the biology of melanoma and identify novel therapeutic strategies.
Furthermore, there is growing understanding of the regulation of metabolic phenotypes in this disease by both intrinsic signaling aberrations and extrinsic signaling by the TME. Finally, there is also growing evidence that the metabolic state of the tumor cells can affect the surrounding TME, with implications for both targeted and immune therapies.
Additional investigation is needed to further define the interplay between metabolic pathways and oncogenic signaling pathways characteristic of melanoma. Further defining how metabolic pathways cooperate with each other and the TME to promote melanoma progression and metastasis should also be investigated. In addition, our understanding of how melanoma signaling networks hijack the met- ples from patients and in vivo preclinical models will likely be necessary to address these highly relevant questions.
Targeting metabolic pathways remains a difficult task due to toxicity, as well as the metabolic flexibility of melanoma cells. While some activity with single agents has been observed in preclinical models, metabolic inhibitors will likely be most useful in combination with approved targeted and/or immune therapies. Further, the likelihood of success for such strategies will be enhanced by the development of biomarkers that can be used to select patients most likely to benefit from metabolic inhibitors.
The field of melanoma metabolism has moved far beyond an exclusive focus on the Warburg effect. While aerobic glycolysis still plays a central role in melanoma metabolism, this review has highlighted additional pathways that also contribute to tumorigenesis and metastasis.
Each of these pathways provides an array of therapeutic targets that could translate to novel treatments for this highly aggressive, metabolically heterogeneous disease.
